Irisin treatment partially reversed doxorubicin-induced perivascular fibrosis and cardiotoxicity by inhibiting endothelial-to-mesenchymal transition via regulation of ROS accumulation and autophagy.
Does irisin treatment ameliorate doxorubicin-induced cardiac perivascular fibrosis and cardiotoxicity in a mouse model?
Irisin protects against doxorubicin-induced cardiotoxicity and perivascular fibrosis by inhibiting endothelial-to-mesenchymal transition through UCP2 regulation.
The dose-dependent toxicity to cardiomyocytes has been well recognized as a central characteristic of doxorubicin (DOX)-induced cardiotoxicity (DIC), however, the pathogenesis of DIC in the cardiac microenvironment remains elusive. Irisin is a new hormone-like myokine released into the circulation in response to exercise with distinct functions in regulating apoptosis, inflammation, and oxidative stress. Recent advances revealed the role of irisin as a novel therapeutic method and an important mediator of the beneficial effects of exercise in cardioprotection. Here, by using a low-dose long-term mouse DIC model, we found that the perivascular fibrosis was involved in its myocardial toxicity with the underlying mechanism of endothelial-to-mesenchymal transition (EndMT). Irisin treatment could partially reverse DOX-induced perivascular fibrosis and cardiotoxicity compared to endurance exercise. Mechanistically, DOX stimulation led to excessive accumulation of ROS, which activated the NF-κB-Snail pathway and resulted in EndMT. Besides, dysregulation of autophagy was also found in DOX-treated endothelial cells. Restoring autophagy flux could ameliorate EndMT and eliminate ROS. Irisin treatment significantly alleviated ROS accumulation, autophagy disorder, NF-κB-Snail pathway activation as well as the phenotype of EndMT by targeting uncoupling protein 2 (UCP2). Our results also initially found that irisin was mainly secreted by cardiomyocytes in the cardiac microenvironment, which was significantly reduced by DOX intervention, and had a protective effect on endothelial cells in a paracrine manner. In summary, our study indicated that DOX-induced ROS accumulation and autophagy disorders caused an EndMT in CMECs, which played a role in the perivascular fibrosis of DIC. Irisin treatment could partially reverse this phenomenon by regulating UCP2. Cardiomyocytes were the main source of irisin in the cardiac microenvironment. The current study provides a novel perspective elucidating the pathogenesis and the potential treatment of DIC.
Pan et al. (Tue,) conducted a other in Doxorubicin-induced cardiotoxicity (n=40). Irisin vs. Vehicle / DOX alone was evaluated on Cardiac function (ejection fraction and fractional shortening) and perivascular fibrosis. Irisin treatment partially reversed doxorubicin-induced perivascular fibrosis and cardiotoxicity by inhibiting endothelial-to-mesenchymal transition via regulation of ROS accumulation and autophagy.